<DOC>
	<DOCNO>NCT01930812</DOCNO>
	<brief_summary>The purpose study compare , patient prostate breast cancer , accuracy 18F-NaF PET image 99mTc whole body bone scan single-photon emission compute tomography ( SPECT ) .</brief_summary>
	<brief_title>18F-NaF PET Imaging Bone Scintigraphy</brief_title>
	<detailed_description>Technetium-99m ( 99mTc ) widely use radionuclide diagnostic nuclear medicine study . It use 20 million diagnostic procedure worldwide annually . It become popular radioisotope easy availability 99Molybdenum ( 99Mo ) /99mTc generator , historic low cost , previous high availability . The National Research Universal ( NRU ) reactor Chalk River Laboratories ( Ontario , Canada ) shut unexpectedly May 2009 follow leak heavy water . The NRU reactor supply approximately third world 's demand 99Mo 99Mo/99mTc generator use diagnostic nuclear medicine test . Given fragility 99Mo supply , alternative radiopharmaceutical , 18F-Sodium Fluoride ( 18F-NaF ) , attractive option replace 99mTc bone scan . Several study suggest 18F-NaF may accurate sensitive detection bone metastases 99mTc bone scan .</detailed_description>
	<mesh_term>Sodium Fluoride</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<mesh_term>Listerine</mesh_term>
	<criteria>All Subject Inclusion Criteria All subject must WHO performance status 02 . Subjects ≥ 18/19 year age ( depend age majority province trial conduct ) For Prostate Cancer : Male subject require bone scan evaluation bone metastasis one ( ) follow criterion : Symptomatic subject clinically suspect bone metastasis base history nonjoint skeletal pain nonjoint skeletal tenderness physical examination . The physician must high index suspicion base history physical examination , night time pain new onset pain unexplained trauma . Such subject must measurable PSA level ≥ 4 ng/mL . Subjects findings examination ( plain xray , CT , MRI bone scintigraphy others ) suspicious bone metastases conclusively diagnostic bone metastasis . Asymptomatic subject newly diagnose localized prostate cancer [ 1 ] biopsy Gleason sum 8 10 ( e.g . score 3+5 , 5+3 , 4+4 , 4+5 , 5+4 5+5 ) prior treatment . Asymptomatic subject newly diagnose localized prostate cancer [ 1 ] biopsy Gleason score ( 4+3 ) either PSA level ≥ 20 palpable disease ( cT2b great ) prior treatment . Asymptomatic subject newly diagnose localized prostate cancer [ 1 ] PSA level ≥ 20 palpable disease ( cT2 great ) prior treatment . Asymptomatic subject prior history treat prostate cancer , rise PSA , PSA double time &lt; 6 month , minimum PSA level ≥ 4 ng/mL Asymptomatic subject prior history treated prostate cancer , rise PSA androgen deprivation therapy , clearly measurable PSA doubling time &lt; 6 month ( treatment need discontinue eligibility ) . Notes : [ 1 ] Subjects newly diagnose prostate cancer receive androgen deprivation therapy , duration &lt; 6 month time enrolment , prior radiation therapy surgery , remain eligible participate study meet inclusion criterion . For Breast Cancer : Subjects ( male female ) require bone scan evaluation bone metastasis one ( ) follow criterion ( 1923 ) : Symptomatic subject clinically suspect bone metastasis base history nonjoint skeletal pain nonjoint skeletal tenderness physical examination . The physician must high index suspicion base history physical examination , night time pain new onset pain unexplained trauma . Subjects findings examination ( plain xray , CT , MRI bone scintigraphy others ) suspicious bone metastases conclusively diagnostic bone metastasis . Asymptomatic subject newly diagnose extraskeletal metastatic breast cancer ( stage IV ) . Asymptomatic subject elevate serum cancer antigen ( CA ) 15.3 alkaline phosphatase newly diagnose locally advanced breast cancer ( Stage III ) . Asymptomatic subject nodal extraskeletal metastatic relapse followup curativeintent therapy . Asymptomatic subject new elevation CA 15.3 alkaline phosphatase followup curativeintent therapy . Subject Exclusion Criteria Pregnancy . Inability lie supine duration image study . Subjects previously know bone metastasis diagnose image biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>18F-NaF PET/CT</keyword>
	<keyword>Bone imaging</keyword>
</DOC>